Rational use of calcium-channel antagonists in Raynaud's phenomenon.
Curr Opin Rheumatol
; 10(6): 584-8, 1998 Nov.
Article
en En
| MEDLINE
| ID: mdl-9812220
ABSTRACT
Raynaud's phenomenon (RP) is a peripheral circulatory disorder characterized by sudden episodes of digital artery spasm, often precipitated by cold temperature or emotional stress. Although the cause of RP is not fully known, it appears to involve inappropriate adrenergic response to cold stimuli. Treatment of RP is conservative in most patients, but in patients with severe disease includes the use of agents that promote digital vasodilation. The calcium-channel antagonists, particularly the dihydropyridine derivative nifedipine, are the most thoroughly studied drug class for the treatment of RP. Approximately two thirds of patients respond favorably, with significant reductions in the frequency and severity of vasospastic attacks. Nifedipine use is often limited by the appearance of adverse vasodilatory effects such as headache or peripheral edema. The newer second-generation dihydropyridines such as amlodipine, isradipine, nicardipine, and felodipine also appear to be effective in patients with RP and may be associated with fewer adverse effects.
Buscar en Google
Bases de datos:
MEDLINE
Métodos Terapéuticos y Terapias MTCI:
Terapias_biologicas
/
Aromoterapia
Asunto principal:
Enfermedad de Raynaud
/
Bloqueadores de los Canales de Calcio
Idioma:
En
Revista:
Curr Opin Rheumatol
Año:
1998
Tipo del documento:
Article
País de afiliación:
Estados Unidos